203 related articles for article (PubMed ID: 30243941)
21. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
22. Mutations of
Tsyganov MM; Sorokovikova SS; Lutzkaya EA; Ibragimova MK
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628606
[TBL] [Abstract][Full Text] [Related]
23. Prevalence of PALB2 mutations in Australasian multiple-case breast cancer families.
Teo ZL; Park DJ; Provenzano E; Chatfield CA; Odefrey FA; Nguyen-Dumont T; ; Dowty JG; Hopper JL; Winship I; Goldgar DE; Southey MC
Breast Cancer Res; 2013 Feb; 15(1):R17. PubMed ID: 23448497
[TBL] [Abstract][Full Text] [Related]
24. Association of PALB2 sequence variants with the risk of early-onset breast cancer in patients from Turkey.
Cecener G; Guney Eskiler G; Egeli U; Tunca B; Alemdar A; Gokgoz S; Tasdelen I
Mol Biol Rep; 2016 Nov; 43(11):1273-1284. PubMed ID: 27573125
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
[TBL] [Abstract][Full Text] [Related]
26. Gene of the month: PALB2.
Hamdan O; Nowak KM
J Clin Pathol; 2023 Feb; 76(2):73-75. PubMed ID: 36600573
[TBL] [Abstract][Full Text] [Related]
27. Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer.
Nakagomi H; Sakamoto I; Hirotsu Y; Amemiya K; Mochiduki H; Omata M
Int J Clin Oncol; 2016 Apr; 21(2):270-275. PubMed ID: 26411315
[TBL] [Abstract][Full Text] [Related]
28. Murine models for familial pancreatic cancer: Histopathology, latency and drug sensitivity among cancers of Palb2, Brca1 and Brca2 mutant mouse strains.
Park D; Shakya R; Koivisto C; Pitarresi JR; Szabolcs M; Kladney R; Hadjis A; Mace TA; Ludwig T
PLoS One; 2019; 14(12):e0226714. PubMed ID: 31877165
[TBL] [Abstract][Full Text] [Related]
29. The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk.
Catucci I; Radice P; Milne RL; Couch FJ; Southey MC; Peterlongo P
Breast Cancer Res; 2016 Nov; 18(1):111. PubMed ID: 27829436
[No Abstract] [Full Text] [Related]
30. Pan-cancer analysis of co-occurring mutations in RAD52 and the BRCA1-BRCA2-PALB2 axis in human cancers.
Hamid AB; Frank LE; Bouley RA; Petreaca RC
PLoS One; 2022; 17(9):e0273736. PubMed ID: 36107942
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
Fernandes PH; Saam J; Peterson J; Hughes E; Kaldate R; Cummings S; Theisen A; Chen S; Trost J; Roa BB
Cancer; 2014 Apr; 120(7):963-7. PubMed ID: 24415441
[TBL] [Abstract][Full Text] [Related]
32. Frequent Abnormal Pancreas Imaging in Patients With Pathogenic ATM, BRCA1, BRCA2, and PALB2 Breast Cancer Susceptibility Variants.
Lucas AL; Fu Y; Labiner AJ; Dimaio CJ; Sethi A; Kastrinos F
Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2686-2688.e2. PubMed ID: 36087707
[No Abstract] [Full Text] [Related]
33. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
[TBL] [Abstract][Full Text] [Related]
34. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
35. A PALB2 germline mutation associated with hereditary breast cancer in Italy.
Papi L; Putignano AL; Congregati C; Piaceri I; Zanna I; Sera F; Morrone D; Genuardi M; Palli D
Fam Cancer; 2010 Jun; 9(2):181-5. PubMed ID: 19763884
[TBL] [Abstract][Full Text] [Related]
36. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
[TBL] [Abstract][Full Text] [Related]
37. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma.
Takeuchi S; Doi M; Ikari N; Yamamoto M; Furukawa T
Sci Rep; 2018 May; 8(1):8105. PubMed ID: 29802286
[TBL] [Abstract][Full Text] [Related]
38. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
[TBL] [Abstract][Full Text] [Related]
39. PALB2: a novel inactivating mutation in a Italian breast cancer family.
Balia C; Sensi E; Lombardi G; Roncella M; Bevilacqua G; Caligo MA
Fam Cancer; 2010 Dec; 9(4):531-6. PubMed ID: 20852946
[TBL] [Abstract][Full Text] [Related]
40. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
